Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) provide greater weight reduction and better metabolic control compared to GLP-1 receptor mono-agonists.
If you are not achieving sufficient weight loss with a GLP-1 medication like semaglutide, switching to a dual GIP/GLP-1 agonist like tirzepatide may offer greater benefits. Clinical trials show that tirzepatide can lead to even more significant weight loss compared to existing GLP-1 drugs. This makes it a strong option for those who need more aggressive treatment.
GIP/GLP-1 dual-agonism appear to provide better metabolic control and greater weight reduction compared with GLP-1-R mono-agonism.
Why this rating
Supported by direct comparisons in Phase 3 trials (e.g., STEP 2 comparing semaglutide to liraglutide, and SURMOUNT trials showing high efficacy of tirzepatide).
Source
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes
Thomas Först et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16247
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →